Importantly, treatment with CaSR NAM restored the baseline expression of these genes in our in vitro IPF model, suggesting a potential role for the abovementioned metabolic dysregulation in IPF through the activation of CaSR. The gene discussed is CASR; the disease is idiopathic pulmonary fibrosis.